Collectively, these studies demonstrate that targeted inhibition of the NLRP3 inflammasome represents a promising therapeutic strategy for the gastric inflammatory disorders investigated in these models, namely gastric ulcer and chronic atrophic gastritis. This evidence concerns the gene NLRP3 and gastritis.